Negative Cultures: Patient Education for Recurrent, Chronic, or Complicated Urinary Tract Infections
Many patients with recurrent, chronic, or complicated urinary tract infections experience frustration when their lab cultures come back negative despite ongoing symptoms. As many as 1 in 3 urine cultures return negative even when the patient has a true UTI. This white paper, developed in partnership between Biotia and Clinova Solutions, helps patients and their providers understand why standard culture-based testing can miss real infections, what newer molecular diagnostic approaches like next-generation sequencing offer, and when advanced testing such as the BIOTIA-ID Urine Test may be appropriate. It also reviews non-infectious causes of UTI-like symptoms and the important difference between colonization and infection — equipping patients with the knowledge to advocate for the right care.
Next-generation sequencing is improving pathogen detection and antimicrobial stewardship.
1 in 3 urine cultures return negative — even when the patient has a true UTI (Heytens et al., 2017).
In a study of 200 culture-negative patients at SUNY Downstate, the BIOTIA-ID Urine Test detected key urogenital pathogens in 63% of samples — half of which were polymicrobial.
In 70% of those cases, the antibiotic the patient had been prescribed would have had no effect on the actual pathogen detected.
What is culture-based testing?
If you have ever had a urine sample sent to a lab, you may have heard your provider say they were “sending it for culture.” It is a phrase that gets used often, but rarely explained. Culture-based testing is a laboratory method that works by growing microorganisms — like bacteria and fungi — in a controlled environment, typically in a petri dish containing nutrients that allow those organisms to multiply. If bacteria are present in your sample, they grow into visible colonies that lab professionals can identify and study. From there, providers can determine what organism may be causing an infection and, in many cases, which antibiotics it responds to. This method has been a cornerstone of clinical microbiology since the 1800s, and for many straightforward infections it works well. For patients with recurrent, complicated, or persistent urinary symptoms, however, culture-based testing has recognized limitations. Understanding how culture-based testing works — and where its limitations lie — is an important first step in understanding why some patients continue to experience symptoms without a clear diagnosis, and why newer testing approaches are being explored to help fill those gaps.
Why standard cultures can come back negative despite symptoms
Standard urine and vaginal cultures are designed to detect common pathogens by growing bacteria and fungi from the specimen collected from the patient. Patients with urinary tract infection symptoms or vaginal discomfort often face frustration when lab cultures come back negative or unchanged despite ongoing symptoms. It is not unusual for women to report classic UTI symptoms — burning, urgency, and frequency, among others — even when urine cultures show no significant bacterial or fungal growth. In fact, as many as 1 in 3 urine cultures will come back negative even though the patient has a UTI [1]. Limitations include one-size-fits-all thresholds across species and clinical cases, pathogens needing different growth requirements, slow growth rates, complications in identifying polymicrobial infections, low microbial burden, and timing of collection. Thresholding challenges. Traditional urine culture techniques use a specific threshold to define a “positive” infection, chosen based on studies of kidney infections in the 1950s. More recent research shows that in symptomatic bladder infections, bacterial counts below current threshold guidance — especially for E. coli — can indicate infection. High fluid intake or frequent urination can dilute pathogens in the urine, and testing during or directly following treatment may increase the risk of false-negative results. Guidelines advise that in patients who still have UTI symptoms after treatment, a repeat urine culture should be obtained, while routine “test of cure” cultures are not recommended in patients without symptoms. Growth challenges. Standard culture media and techniques are optimized for common bacteria like E. coli. Less common organisms — such as Ureaplasma urealyticum, Mycoplasma species, or Chlamydia trachomatis — do not grow on routine culture plates. Trichomonas vaginalis can cause vaginal burning or urethritis but would be missed by routine bacterial cultures. Fungal infections might also be overlooked if the lab is only looking for bacteria. A “negative” culture could simply mean the test was not suited to find the actual culprit. Sampling challenges. In one study, 90.5% of women with UTI symptoms but a negative culture were found to have E. coli DNA in their urine by molecular testing [1]. A negative culture does not always equal “no infection” — it may mean bacteria were at low levels or did not successfully grow in the laboratory. Some bacteria can persist inside the bladder walls, evading antibiotics and the immune system, to later reactivate and cause UTI symptoms to return. Vaginal microbiome challenges. Patients experiencing urinary symptoms may benefit from evaluation of the vaginal environment. Because the urethra and vagina are anatomically adjacent, certain vaginal conditions can contribute to symptoms that overlap with urinary tract infection. First-line vaginal testing is typically culture-based and shares many of the same limitations as urine culture: results can be influenced by site sampled, hormonal status, recent sexual activity, menstruation, and contraceptive use. Polymicrobial challenges. A patient’s urine culture might repeatedly grow a small amount of the same bacteria that neither increases nor is eliminated. Standard lab definitions might label such low counts as “contamination” or insignificant, even though the patient’s symptoms suggest otherwise. Emerging research suggests that for patients with persistent symptoms, laboratories should report all growth regardless of quantity, and consider lowering the threshold for a positive result.
Molecular approaches to diagnosing culture-negative UTIs
Where culture-based methods attempt to grow any pathogens that may be in a urine or vaginal sample, newer laboratory methods look for the presence and sequence of pathogen DNA. These approaches are called molecular diagnostics, and they have significantly improved sensitivity and specificity over traditional culture-based methods. The most common molecular method, familiar from the COVID-19 pandemic, is polymerase chain reaction (PCR). PCR tests for urinary tract infections work by making millions of copies of a unique piece of a pathogen’s DNA, which is tracked by the PCR machine. PCR tests can cover several different pathogens or antimicrobial resistance genes from a single test in “panels.” As with culture-based methods, PCR has limitations: it is pre-designed to test for the most common UTI-causing pathogens, and if a pathogen is not on the panel it will not be reported as present. There are limits to the total number of targets you can include — usually between 4 and 20 pathogens. Patients should feel empowered to ask which pathogens are included in any PCR panel ordered for them. Clinical metagenomics, which uses next-generation sequencing, is rapidly changing how providers diagnose and treat urinary tract infections. Rather than growing pathogens or looking for specific DNA fragments, clinical metagenomic tests make copies of all DNA present in the sample. Software then compares the DNA found to a curated reference database of microorganisms. This approach is “pathogen-agnostic,” meaning any pathogen may be identified — the test does not need to be pre-designed and so does not face the same limitations PCR faces. Some clinical metagenomic tests also provide insight into antimicrobial resistance by identifying genes that enable pathogens to evade different treatments.
The BIOTIA-ID Urine Test
In a study of 200 culture-negative patients at SUNY Downstate Hospital, the BIOTIA-ID Urine Test found key urogenital pathogens in 63% of the samples, with 50% of these positives containing multiple pathogens, indicating a polymicrobial infection. Many of these pathogens would be difficult to grow or would not have grown at all via traditional urine culture. When looking back at what the providers had prescribed to treat the patient’s symptoms, in 70% of cases the prescribed drug would have had no effect on the pathogen detected [2]. These findings highlight the importance of pursuing advanced molecular diagnostic testing in the face of recurrent or persistent UTI symptoms to truly rule out infectious causes and guide next steps. Key differentiators between the BIOTIA-ID Urine Test and other tests that leverage next-generation sequencing approaches for UTIs are its untargeted approach and clinical rigor. Targeted sequencing looks at a small part of pathogen genomes; untargeted sequencing looks at all pathogen genomes. When you only look at a small section, it is harder to identify the species or characterize it, harder to identify pathogens at a strain level, and harder to detect antimicrobial resistance genes unless specifically designed to do so. Clinical metagenomic tests overcome the limitations of targeted sequencing approaches but still have considerations. The first is overdiagnosis. Many microbes may not be clinically relevant, causing unnecessary stress to patients. Rather than reporting every organism detected, the BIOTIA-ID Urine Test was validated to detect 44 key urogenital pathogens and 15 different antibiotic resistance markers. The second consideration is cost. Providers should consider whether the information generated will truly be actionable and if the test has undergone thorough clinical evaluation. Payors, regulators, and diagnostics companies like Biotia are increasingly working together to get these tests covered by insurance.
Post-UTI hypersensitivity syndrome and non-infectious causes of UTI-like symptoms
Not all persistent urinary or vaginal symptoms are related to an ongoing infection. Repeated infections or inflammation can lead to lasting changes in the bladder and nervous system, sometimes called post-UTI hypersensitivity syndrome. After a particularly severe or prolonged UTI, some patients continue to experience bladder irritation — urgency, pain, frequent urination — even after the infection has been cleared. The bladder wall may remain inflamed, and the sensory nerves within the bladder can become sensitized, leading to persistent urgency, frequency, and pelvic discomfort even after bacterial clearance. Crucially, this is a scenario where giving more antibiotics will not help, since the symptoms are due to residual inflammation and nerve upregulation rather than an ongoing infection. Other non-infectious conditions can produce symptoms very similar to UTIs and should be considered when cultures are repeatedly normal: • Interstitial cystitis (IC): a chronic condition of bladder pain, urinary frequency, and urgency, with cultures typically negative. Patients with IC are commonly misdiagnosed and given many antibiotics before the true diagnosis is recognized. • Overactive bladder (OAB): the bladder muscle contracts inappropriately, causing sudden urgency and frequency without infection. • Pelvic floor muscle dysfunction: tightness or spasms can cause urinary frequency, urgency, and burning. • Urethral syndrome: an older term for UTI-like symptoms — especially urethral burning and urgency — without infection, often linked to irritants or muscle issues. • Post-menopausal atrophic vaginitis: low estrogen levels after menopause lead to vaginal and urethral tissue thinning and dryness, causing burning, irritation, and a feeling of needing to urinate often. • Chemical cystitis: bladder irritation caused by hygiene products, spermicides, douches, fragranced soaps, bubble baths, certain lubricants, chemotherapy agents, or concentrated urine from dehydration. • Incomplete emptying: residual urine in the bladder after voiding can cause urinary frequency, urgency, weak stream, hesitancy, or recurrent “UTI-like” symptoms with negative cultures. • Nephrolithiasis (kidney or bladder stones): stones can irritate the urinary tract and cause urgency, frequency, dysuria, hematuria, flank pain, or pelvic discomfort, with sterile culture. • Poor glycemic control: elevated blood glucose can promote urinary frequency and irritation; chronic hyperglycemia can also affect bladder innervation. • Chronic nonbacterial prostatitis / chronic pelvic pain syndrome: in men, presents with urinary frequency, urgency, dysuria, and perineal discomfort without evidence of active infection on culture. If multiple reliable cultures are negative despite symptoms, clinicians are advised to pause and reconsider the diagnosis. Red flags like blood in the urine, severe pain, or other abnormalities might prompt further investigations to rule out other pathologies. The emphasis is on symptom management and restoring quality of life, rather than eradicating an infection. When cultures remain negative, it is crucial to avoid repeated antibiotic courses and instead treat the bladder’s hypersensitivity and any functional issues.
Colonization vs. infection: understanding asymptomatic bacteriuria
When interpreting results, it is essential to distinguish true infection from colonization. Colonization means bacteria are present in the body — for instance, in the urine or vagina — but are not causing harm or symptoms. An example is asymptomatic bacteriuria (ASB), when a urine culture finds a significant amount of bacteria in the urine in the absence of UTI symptoms. ASB is common, especially in older adults, people with diabetes, or those with urinary catheters. Medical guidelines emphasize that asymptomatic bacteriuria should not be treated with antibiotics in most cases [3]. Treating a colonization does not confer benefit and can actually cause harm. The Infectious Diseases Society of America recommends screening and treating ASB only in very specific situations: pregnant women, or patients about to undergo invasive urinary procedures. In almost all other scenarios — including the elderly in nursing homes, people with diabetes, and people with catheters — finding bacteria in the urine without symptoms should be managed with watchful observation, not antibiotics. A positive culture alone is not always cause for alarm if symptoms are absent, and conversely a negative culture does not guarantee absence of an issue if symptoms are present. Sometimes patients have both: a baseline colonization and intermittent true UTIs on top of that. Doctors sort this out by correlating cultures with symptoms and inflammatory markers. As a patient, understanding this distinction can prevent confusion. If you feel like you have a UTI but your culture is “no growth” or shows only tiny amounts of bacteria, that should prompt your provider to try a different diagnostic testing method as well as look for alternate explanations for your symptoms.
Conclusion
In scenarios of persistent symptoms with negative cultures, understanding the limitations of urine and vaginal cultures is key to addressing the root cause of your symptoms. Less common pathogens or improper specimen collection may explain why culture results are returning negative despite ongoing symptoms. Advanced diagnostic testing can play an important role in improving health outcomes, particularly for patients with persistent, recurrent, or culture-negative urinary symptoms. Improved diagnostic precision can translate into better symptom resolution, fewer recurrent episodes, reduced antibiotic resistance pressure, lower healthcare utilization, and improved quality of life. Importantly, advanced testing should not replace clinical judgment, but rather serve as an adjunct that enhances individualized care, supports antimicrobial stewardship, and helps differentiate infectious processes from non-infectious causes of lower urinary tract symptoms. In these instances, asking your provider for a molecular diagnostic test may improve pathogen detection while non-infectious causes of your symptoms are investigated.
References
- Heytens S, et al. Women with symptoms of a urinary tract infection but a negative urine culture: PCR-based quantification of Escherichia coli suggests infection in most cases. Clinical Microbiology and Infection. 2017;23(9):647–652.
- Romero E, et al. Utilization of clinical-grade metagenomics in culture-negative urine specimens from high-risk patients with suspected urinary tract infection. Biotia. 2026 (manuscript in preparation).
- Nicolle LE, et al. IDSA 2019 Clinical Practice Guideline Update for the Management of Asymptomatic Bacteriuria. Clinical Infectious Diseases. 2019;68(10):e83–e110.
- Wangprapa P, et al. Analytical validation of a metagenomic next-generation diagnostic platform for urinary tract infection in a Thai tertiary hospital setting: a BI-Biotia UTI cohort study. Frontiers in Cellular and Infection Microbiology. 2026;16:1751074.